Compare ROIV & INGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROIV | INGR |
|---|---|---|
| Founded | 2014 | 1906 |
| Country | United Kingdom | United States |
| Employees | 721 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 6.3B |
| IPO Year | 2021 | 1997 |
| Metric | ROIV | INGR |
|---|---|---|
| Price | $38.22 | $97.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | $28.94 | ★ $128.57 |
| AVG Volume (30 Days) | ★ 8.4M | 533.2K |
| Earning Date | 05-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 2.94% |
| EPS Growth | N/A | ★ 15.14 |
| EPS | N/A | ★ 4.01 |
| Revenue | $8,260,000.00 | ★ $7,219,000,000.00 |
| Revenue This Year | N/A | $3.86 |
| Revenue Next Year | $744.61 | $2.95 |
| P/E Ratio | ★ N/A | $24.20 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.50 | $94.44 |
| 52 Week High | $42.50 | $123.49 |
| Indicator | ROIV | INGR |
|---|---|---|
| Relative Strength Index (RSI) | 54.96 | 38.33 |
| Support Level | $33.15 | $98.04 |
| Resistance Level | $42.50 | $105.06 |
| Average True Range (ATR) | 1.43 | 1.84 |
| MACD | -0.04 | -0.46 |
| Stochastic Oscillator | 59.26 | 18.97 |
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Ingredion is an ingredients provider for the food, beverage, brewing, and animal nutrition industries. The company processes corn, tapioca, potatoes, stevia, grains, fruits, gums, and vegetables into value-added ingredients. The company sells specialty ingredients that include starch-based texturizers and natural alternative sweeteners such as stevia. Ingredion also sells commodity ingredients that include sweeteners, such as high-fructose corn syrup, and starches, such as those used for sustainable packaging, as well as plant-based proteins. The company plans to acquire Tate & Lyle in an all-cash deal that should close in 2027.